Study on the influence of retinal detachment reattachment surgery on choroidal blood flow and its mechanism

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2600126235

Enrollment

Unknown

Registered

2026-06-05

Start date

2026-06-20

Completion date

Unknown

Last updated

2026-06-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rhegmatogenous retinal detachment (RRD)

Interventions

Pars Plana Vitrectomy (PPV) group:None

Control group:None

Scleral buckling surgery (SB) Group:None

Eligibility

Sex/Gender

All

Age

15 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. PPV group:Retinal detachment patients undergoing pars plana vitrectomy, aged 15 or older with informed consent, with no gender restrictions; 2. SB group:Retinal detachment patients undergoing scleral buckling, aged 15 or older with informed consent, with no gender restrictions; 3. Control group:Patients with retinal detachment who are >=15 years old with signed informed consent and no gender restriction, undergoing retinal detachment reattachment surgery in the other eye.

Exclusion criteria

Exclusion criteria: 1. PPV group: Any previous eye surgery other than pars plana vitrectomy, history of retinal diseases (such as choroidal neovascularization, diabetic retinopathy, and central serous chorioretinopathy), glaucoma, spherical equivalent >=6 diopters (D), anisometropia >=1.5 D, poor image quality, and missing medical records; 2. SB gtoup: Any previous eye surgery other than scleral buckling, history of retinal diseases (such as choroidal neovascularization, diabetic retinopathy, and central serous chorioretinopathy), glaucoma, spherical equivalent >=6 diopters (D), anisometropia >=1.5 D, poor image quality, and missing medical records; 3. Control group: Any previous eye surgery , history of retinal diseases (such as choroidal neovascularization, diabetic retinopathy, and central serous chorioretinopathy), glaucoma, spherical equivalent >=6 diopters (D), anisometropia >=1.5 D, poor image quality, and missing medical records;

Design outcomes

Primary

Measure	Time frame
Choroidal blood flow and structural indicators:Choroidal Thickness, CT?Choroidal Vascularity Index, CVI?Choroidal Stroma volume Index, CSI?Choriocapillaris Flow Density;	—

Secondary

Measure	Time frame
Anterior chamber and ciliary body related indicators: ACD, Anterior Chamber Depth?ACV, Anterior Chamber Volume?ARW,Angle Recess Width?SSD,Scleral Spur Distanc?SSA500,Scleral Spur Angle at 500µm, etc.;Iris Blood Flow Density;Retinal blood flow and structural indicators: FAZ,Foveal Avascular Zone Area index?Superficial and deep Vascular Complex Vessel Density?Retinal Thicknes;	—

Countries

China

Contacts

Public ContactHu Jie

The Zhongshan Ophthalmic Center,Sun Yat-sen University

hehujie@126.com+86 20 87330411

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jun 11, 2026